Heterologous 2F5 Epitope-Scaffold Prime: Boosting Immuno-Focuses B Cell Responses to the HIV-1 gp41 2F5 Neutralization Determinant
2011

Heterologous Prime-Boosting for HIV-1 Vaccine Responses

Sample size: 15 publication Evidence: moderate

Author Information

Author(s): Guenaga Javier, Dosenovic Pia, Ofek Gilad, Baker David, Schief William R., Kwong Peter D., Karlsson Hedestam Gunilla B., Wyatt Richard T.

Primary Institution: Vaccine Research Center, National Institutes of Health

Hypothesis

Can heterologous prime-boost immunization strategies effectively enhance antibody responses against the HIV-1 2F5 epitope?

Conclusion

The study found that heterologous prime-boost immunization regimens can effectively focus the immune response on the HIV-1 2F5 epitope, but did not elicit neutralizing antibodies.

Supporting Evidence

  • The study demonstrated that the heterologous prime-boosting regimen increased antibody responses to the 2F5 epitope.
  • Incorporating a T cell helper epitope in the immunogens resulted in higher antibody titers against the 2F5 graft.
  • Two epitope scaffolds boosted responses when primed with a more immunogenic scaffold.

Takeaway

Scientists are trying to make vaccines better by using different shots to help the body recognize and fight off HIV better.

Methodology

The study used a series of immunizations in mice with different epitope scaffolds to measure antibody responses.

Limitations

The study did not achieve neutralizing antibody responses against HIV-1 despite effective B cell responses.

Participant Demographics

Adult female C57BL/6 mice were used for the immunization experiments.

Digital Object Identifier (DOI)

10.1371/journal.pone.0016074

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication